Corona Remedies Ltd

Corona Remedies Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will be shut from October 01, 2026, and will reopen 48 hours after the declaration of the unaudited financial results for the second quarter and half year ending September 30, 2026. The specific date for the board meeting to consider these financial results will be communicated separately.

Sepia Investments Limited, Sage Investment Trust, and Anchor Partners have disclosed the sale of equity shares in Corona Remedies Limited. Sepia Investments sold 2,485,476 shares, Sage Investment Trust sold 51,641 shares, and Anchor Partners sold 92,763 shares. This disclosure was made under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Sepia Investments Limited, Sage Investment Trust, and Anchor Partners, acting in concert, have disclosed the sale of a combined 2,630,880 equity shares in Corona Remedies Limited. This transaction, reported under SEBI's SAST Regulations, involved Sepia Investments selling 2,485,476 shares, Sage Investment Trust selling 51,641 shares, and Anchor Partners selling 92,763 shares. The sellers were previously holding significant stakes in the company, with Sepia Investments holding 12.68%, Sage Investment Trust 0.26%, and Anchor Partners 0.47% before this disposal. The disclosure indicates a substantial change in the shareholding structure of Corona Remedies Limited, which is listed on both BSE and NSE.

Corona Remedies Ltd has responded to a clarification request from the BSE regarding a recent increase in trading volume. The company stated that it is compliant with SEBI regulations and has promptly disclosed all material information. They confirmed there is no undisclosed price-sensitive information or impending corporate action. The increase in share volume is attributed purely to market-driven factors. Corona Remedies reiterated its commitment to ongoing compliance with disclosure requirements.

Corona Remedies Ltd reported a strong start to FY27 with unaudited financial results for Q1FY27. Revenue from operations grew by 21.9% year-on-year to ₹422.4 Cr, driven by robust brand building and operational excellence. Profit After Tax (PAT) increased by 30.1% year-on-year to ₹60.1 Cr, with PAT margins improving by 90 basis points to 14.2%. The company continues to outperform the Indian Pharmaceutical Market (IPM) and has moved up to the 26th rank. Key business highlights include the inauguration of an EU-GMP approved Female Hormone Manufacturing Facility and the integration of the acquired brand Wokadine. The company remains focused on core therapies like Women's Healthcare and Cardio-diabetes.

Corona Remedies Ltd announced the outcome of its Board Meeting held today, wherein the Board approved the unaudited standalone and consolidated financial results for the first quarter and three months ended June 30, 2026. The company also approved the limited review reports for the same period. These results will be published in an advertisement as per listing regulations and will be available on the company's website. The Board meeting commenced at 3:00 p.m. and concluded at 4:00 p.m.

Corona Remedies opened FY27 with a clean growth print: consolidated revenue rose 21.9% YoY to ₹422.4 Cr and net profit climbed 30.1% YoY to ₹60.1 Cr (₹46.2 Cr a year ago), with net margin widening ~90 bps to 14.2%. Profit outgrew revenue with no help from one-offs — neither the current nor year-ago quarter carries an exceptional item, so the reported +30.1% is also the underlying figure. Standalone tells the same story (PAT ₹60.1 Cr); the consolidated line differs by just ₹0.01 Cr of associate profit, so the two bases are effectively identical here. The margin expansion is operating-led. Management's disclosed EBITDA rose 33.5% to ₹93.1 Cr with EBITDA margin up 190 bps YoY to 22.0%, driven by brand-building and operational leverage: revenue grew faster than employee costs (₹122.1 Cr, +25%) and other expenses (₹129.7 Cr, +14%), while cost of materials stayed contained. Sequentially the print looks even stronger — revenue +19.6% and PAT +32.6% over Q4 FY26's ₹353.1 Cr / ₹45.3 Cr — but Q4 was a soft base, so YoY is the cleaner read. The board declared the results 31 July; the earnings call is set for 3 August. Against the bar, this is a beat-to-meet. Management's FY27 guidance from the Q4 concall was >15% organic revenue growth and >20% PAT growth; Q1 delivered 21.9% and 30.1%, comfortably ahead on both. Street context was thin for this December-2025 IPO — Univest's preview pegged Q1 PAT in a ₹58–74 Cr range, and the actual ₹60.1 Cr lands in the lower-middle of it, so inline rather than a blowout. Operationally, management flags Corona as the fastest-growing among IPM's top-30 for six straight months, rank up three places to 26th (MAT June'26), and 5th in Gynaecology. The quarter also saw commercialisation of the EU-GMP female hormone facility (30 June) and the start of Wokadine integration — both feeding the chronic/women's-health focus that underpins the guidance.

Corona Remedies Ltd has announced that its Board of Directors will convene on July 31, 2026. The primary agenda for this meeting is to consider and approve the company's Unaudited Financial Results for the first quarter and three months ended June 30, 2026. Both standalone and consolidated results will be reviewed. The trading window for the company's securities will remain closed until August 02, 2026, following an earlier intimation regarding insider trading regulations.

Corona Remedies Ltd has announced the commencement of commercial production at its new EU-GMP approved Women's Hormone manufacturing facility located in Bhayla, Ahmedabad. This state-of-the-art facility, inaugurated by Chairman Dr. K. L. Mehta and long-serving women employees, is designed to meet the growing global demand for specialized hormone therapies. The facility boasts advanced manufacturing technologies, including closed-loop systems and precision environmental controls, with an annual capacity of 194 million tablets/capsules and 1.5 million ointments/gels. This expansion is expected to increase the company's in-house hormone manufacturing capacity by nearly 20%, reinforcing its commitment to women's healthcare and strengthening India's pharmaceutical manufacturing capabilities for both domestic and international markets.

Corona Remedies Ltd has announced the inauguration and commencement of commercial production at its EU-GMP approved Women's Hormone manufacturing facility in Bhayla, Ahmedabad. This state-of-the-art facility is designed for specialized hormone manufacturing, featuring segregated operations, precision environmental controls, and advanced containment technologies. It supports multiple dosage forms including tablets, soft gel capsules, ointments, and gels, with an annual capacity of 194 million tablets/capsules and 1.5 million ointments/gels. The facility's commissioning is expected to increase Corona Remedies' in-house hormone manufacturing capacity by nearly 20%, reinforcing its commitment to women's healthcare and strengthening its capabilities for domestic and international markets.